Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0451641 (urolithiasis)
 3,973 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The study aimed at presenting own experience in prevention of new urinary calculi in 18 patients with metabolically active calcium urolithiasis treated with hydrochlorothiazide in daily doses of 100 mg (group I) for 2 years, and in 6 patients with the same disease treated with magnesium oxide in daily doses 300 mg twice a day (group II) for average period of 10 months. In 9 patients a new calculus was formed during the treatment with hydrochlorothiazide, in 7 patients no recurrence was noted, and in 2 remaining patients the results were controversial (coral calculus). Therefore, patients were subdivided into group Ia (failure of hydrochlorothiazide therapy), and group Ib (no recurrence noted). Hydrochlorothiazide did not lead to the stable decrease in the saturation of the urine with calcium oxalate in group Ia whereas in group Ib (without recurrence of urolithiasis) the content of calcium oxalate in the urine was significantly lower than that in group Ia after a 2-year treatment with hydrochlorothiazide (p < 0.01) Recurrence of the disease was seen only in one patient of group II, i.e. treated with magnesium oxide. The treatment of the recurrent calcium urolithiasis is justified and efficient in those patients in whom therapy decreases the content of calcium oxalate in the urine.
 ...
PMID:[Hydrochlorothiazide, allopurinol and magnesium oxide in the treatment of recurrent calcium urolithiasis]. 166 48

We measured urinary oxalate by the method of Hallson and Rose before and during long-term thiazide therapy in 49 patients with recurrent urolithiasis. Urinary oxalate excretion in normal men and women on their usual diets was 38.8 +/- 10.3 mg per day (mean +/- SD) and in patients with calcific renal calculi was 45.9 +/- 14.3 mg per day. Hydrochlorothiazide produced a significant decrease in urinary oxalate excretion in patients treated for more than 12 months (33 +/- 10.6 mg per day). We believe that the thiazide-induced reduction of urinary oxalate excretion is related to reduced intestinal calcium absorption which has been shown during chronic thiazide therapy and may not be evident until 12 or more months of thiazide administration.
 ...
PMID:Reduction of urine oxalate during long-term thiazide therapy in patients with calcium urolithiasis. 741 33

A 5-year-old boy had periodic spasms and startle-induced drop attacks. Zonisamide (ZNS) was partially effective for the former seizures, and propranolol for the latter. An add-on therapy with ACTH resulted in a transient disappearance of seizures and an improvement of EEG. However, the patient developed urolithiasis with resultant hematuria and pyelectasis during ACTH therapy. ZNS can induce urolithiasis by increasing urinary pH and calcium (Ca) excretion, and ACTH may facilitate this rare adverse effect of ZNS by further increasing the urinary Ca. Hydrochlorothiazide could resolve the urolithiasis by decreasing the urinary Ca excretion.
 ...
PMID:[Urolithiasis induced by combined ACTH and zonisamide treatment in a patient with startle induced epilepsy]. 1223 54